|Trade names||Proscar, Propecia, others|
|Synonyms||MK-906; YM-152; L-652,931; 17β-(N-tert-Butylcarbamoyl)-4-aza-5α-androst-1-en-3-one; N-(1,1-Dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide|
|Drug class||5α-Reductase inhibitor|
|Metabolism||Liver (CYP3A4, ALDH)|
Adults: 5–6 hours|
Elderly: >8 hours
|Chemical and physical data|
|Molar mass||372.549 g/mol|
|3D model (JSmol)|
Finasteride, sold under the brand names Proscar and Propecia among others, is a medication used mainly to treat an enlarged prostate or scalp hair loss in men. It can also be used to treat excessive hair growth in women and as a part of hormone therapy for transgender women. It is taken by mouth.
Side effects are generally mild. It may increase the risk of certain rare forms of prostate cancer, and some men may experience sexual dysfunction, depression, anxiety, or breast enlargement. Finasteride is a 5α-reductase inhibitor, and hence is an antiandrogen. It works by decreasing the production of dihydrotestosterone (DHT), an androgen sex hormone, in certain parts of the body like the prostate gland and the scalp. It inhibits two of the three forms of 5α-reductase, and can decrease DHT levels in the blood by up to 70%.
Finasteride was introduced for the treatment of prostate enlargement in 1992 and was approved for the treatment of scalp hair loss in 1997. It was the first 5α-reductase inhibitor to be introduced and was followed by dutasteride a number of years later. The drug is available as a generic medication.
- 1 Medical uses
- 2 Contraindications
- 3 Adverse effects
- 4 Overdose
- 5 Interactions
- 6 Pharmacology
- 7 Chemistry
- 8 History
- 9 Society and culture
- 10 References
Physicians sometimes prescribe finasteride for the treatment of benign prostatic hyperplasia (BPH), informally known as an enlarged prostate. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start and end of urination, and decreased urinary flow. It provides less symptomatic relief than alpha-1 blockers such as tamsulosin and symptomatic relief is slower in onset (six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment). Symptomatic benefits are mainly seen in those with prostate volume > 40 cm3. In long-term studies finasteride but not alpha-1 inhibitors reduce the risk of acute urinary retention (−57% at 4 years) and the need for surgery (−54% at 4 years). If the drug is discontinued, any therapeutic benefits are reversed within about 6–8 months.
A 2010 Cochrane review found a 25 or 26% reduction in the risk of developing prostate cancer with 5α-reductase inhibitor chemoprevention. A followup study of the Medicare claims of participants in a 10-year Prostate Cancer Prevention Trial suggests a significant reduction in prostate cancer risk is maintained even after discontinuation of treatment. However, 5α-reductase inhibitors have been found to increase the risk of developing certain rare but aggressive forms of prostate cancer (27% risk increase), although not all studies have observed this. In addition, there is no negative impact of 5-α-reductase inhibitor on survival rates of people with prostate cancer.
Scalp hair loss
Finasteride is also used to treat male pattern baldness (androgenetic alopecia) in men, a condition that develops in up to 80% of Caucasian men. In the United States, finasteride and minoxidil are the only two FDA approved drugs for the treatment of male pattern hair loss as of 2017. Treatment with finasteride slows further hair loss and provides about 30% improvement in hair loss after six months of treatment, with effectiveness persisting as long as the drug is taken. Taking finasteride leads to a reduction in scalp and serum DHT levels; by lowering scalp levels of DHT, finasteride can maintain or increase the amount of terminal hairs in the anagen phase by inhibiting and sometimes reversing miniaturization of the hair follicle. Finasteride is most effective on the vertex but can reduce hair loss in all areas of the scalp. Finasteride has also been tested for pattern hair loss in women; however, the results were no better than placebo.
Excessive hair growth
Finasteride has been found to be effective in the treatment of hirsutism (excessive facial and/or body hair growth) in women. In a study of 89 women with hyperandrogenism due to persistent adrenarche syndrome, finasteride produced a 93% reduction in facial hirsutism and a 73% reduction bodily hirsutism after 2 years of treatment. Other studies using finasteride for hirsutism have also found it to be clearly effective.
Transgender hormone therapy
Finasteride is sometimes used in hormone replacement therapy for transgender women due to its antiandrogenic effects, in combination with a form of estrogen. However, little clinical research of finasteride use for this purpose has been conducted and evidence of safety or efficacy is limited. Moreover, caution has been recommended when prescribing finasteride to transgender women, as finasteride may be associated with side effects such as depression, anxiety, and suicidal ideation, symptoms that are particularly prevalent in the transgender population and in others at high risk already.
Finasteride may cause birth defects in a male fetus if a pregnant woman takes finasteride or is exposed to finasteride pill fragments. It is classified in the FDA pregnancy category X. Finasteride induces ambiguous genitalia in male fetuses when given to pregnant rhesus monkeys, whereas no abnormalities are observed in female fetuses. There is a single case report of accidental finasteride exposure during pregnancy, although in a female infant.
A 2010 Cochrane review concluded that adverse effects from finasteride are rare when used for BPH. When finasteride was originally approved for hair loss in 1997, the FDA reported that it appeared well tolerated, with the most common side effects being related to sexual function.
The FDA has added a warning to 5α-reductase inhibitors concerning an increased risk of high-grade prostate cancer, as the treatment of BPH lowers PSA (prostate-specific antigen), which could mask the development of prostate cancer. Although overall incidence of male breast cancer in clinical trials for finasteride 5 mg was not increased, there are post-marketing reports of breast cancer in association with its use, though available evidence does not provide clarity as to whether there is a causative relationship between finasteride and these cancers. Some men develop gynecomastia (breast development or enlargement) following finasteride usage. The risk of gynecomastia with 5α-reductase inhibitors is low at about 2.8%.
Finasteride causes short-term sexual dysfunction in some men. Whether finasteride causes long-term sexual dysfunction in some men after stopping drug treatment is unclear. There are case reports of persistent diminished libido or erectile dysfunction after stopping the drug and the FDA has updated the label to inform people of these reports.
The 2010 Cochrane review found that compared with placebo, men taking finasteride are at increased risk for impotence, erectile dysfunction, decreased libido, and ejaculation disorder for the first year of treatment; the rates of these effects became indistinguishable from placebo after 2–4 years and these side effects usually got better over time. Another 2010 review found that when used for hair loss finasteride increased rates of sexual problems. A 2016 meta-analysis found that sexual dysfunction, including erectile dysfunction, loss of libido, and reduced ejaculate, may occur in 3.4 to 15.8% of men treated with finasteride or dutasteride. This adverse effect has been linked to lower quality of life and can cause stress in relationships.
Finasteride has been studied in humans at single doses of up to 400 mg and at continuous dosages of up to 80 mg/day for three months, without adverse effects observed. These doses are many times in excess of the typical dosages of finasteride of 1 mg/day and 5 mg/day that are used clinically. There is no specific recommended antidote for finasteride overdose.
Finasteride is a 5α-reductase inhibitor. It is specifically a selective inhibitor of the type II and III isoforms of the enzyme. By inhibiting these two isozymes of 5α-reductase, finasteride reduces the formation of the potent androgen dihydrotestosterone (DHT) from its precursor testosterone in certain tissues in the body such as the prostate gland, skin, and hair follicles. As such, finasteride is a type of antiandrogen, or more specifically, an androgen synthesis inhibitor.
Finasteride results in a decrease of circulating DHT levels by about 65 to 70% with an oral dosage of 5 mg/day and of DHT levels in the prostate gland by up to 80 to 90% with an oral dosage of 1 or 5 mg/day. In parallel, circulating levels of testosterone increase by approximately 10%, while local concentrations of testosterone in the prostate gland increase by about 7-fold and local testosterone levels in hair follicles increase by around 27 to 53%. An oral dosage of finasteride of only 0.2 mg/day has been found to achieve near-maximal suppression of DHT levels (68.6% for 0.2 mg/day relative to 72.2% for 5 mg/day). Finasteride does not completely suppress DHT production because it lacks significant inhibitory effects on the 5α-reductase type I isoenzyme, with more than 100-fold less inhibitory potency for type I as compared to type II (IC50 = 313 nM and 11 nM, respectively). This is in contrast to inhibitors of all three isoenzymes of 5α-reductase like dutasteride, which can reduce DHT levels in the entire body by more than 99%, In addition to inhibiting 5α-reductase, finasteride has also been found to competitively inhibit 5β-reductase (AKR1D1). However, its affinity for the enzyme is substantially less than for 5α-reductase (an order of magnitude less than for 5α-reductase type I) and hence is unlikely to be of clinical significance.
As of 2012, the tissues in which the different isozymes of 5α-reductase are expressed are not fully clear. This is because different investigators have obtained varying results with different reagents, methods, and tissues examined. However, the different isozymes of 5α-reductase appear to be widely expressed, with notable tissues including the prostate gland, seminal vesicles, testes, epididymides, skin, hair follicles, liver, kidneys, and brain, among others.
By inhibiting 5α-reductase and thus preventing DHT production, finasteride reduces androgen signaling in tissues like the prostate gland and the scalp. In the prostate, this reduces prostate volume, which improves BPH and reduces risk of prostate cancer. Finasteride reduces prostate volume by 20 to 30% in men with benign prostatic hyperplasia. Inhibition of 5α-reductase also reduces epididymal weight, and decreases motility and normal morphology of spermatozoa in the epididymis.
Neurosteroids like 3α-androstanediol (derived from DHT) and allopregnanolone (derived from progesterone) activate the GABAA receptor in the brain; because finasteride prevents the formation of neurosteroids, it functions as a neurosteroidogenesis inhibitor and may contribute to a reduction of GABAA activity. Reduction of GABAA receptor activation by these neurosteroids has been implicated in depression, anxiety, and sexual dysfunction.
The mean oral bioavailability of finasteride is approximately 65%. The absorption of finasteride is not affected by food. At steady-state with 1 mg/day finasteride, mean peak concentrations of finasteride were 9.2 ng/mL (25 nmol/L). Conversely, following a single 5 mg dose of finasteride, mean peak levels of finasteride were 37 ng/mL (99 nmol/L), and plasma concentrations increased by 47 to 54% following 2.5 weeks of continued daily administration. The volume of distribution of finasteride is 76 L/kg. Its plasma protein binding is 90%. The drug has been found to cross the blood–brain barrier, whereas levels in semen were found to be undetectable.
Finasteride is extensively metabolized in the liver, first by hydroxylation via CYP3A4 and then by aldehyde dehydrogenase. It has two major metabolites, which are the tert-butyl side chain monohydroxylated and monocarboxylic acid metabolites. These metabolites show approximately 20% of the inhibitory activity of finasteride on 5α-reductase. Hence, the metabolites of finasteride are not particularly active. The drug has a terminal half-life of 5 to 6 hours in adult men (18–60 years of age) and a terminal half-life of 8 hours or more in elderly men (more than 70 years of age). It is eliminated as its metabolites 57% in the feces and 40% in the urine.
Finasteride, also known as 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androst-1-en-3-one, is a synthetic androstane steroid and 4-azasteroid. It is an analogue of androgen steroid hormones like testosterone and DHT. As an unconjugated steroid, finasteride is a highly lipophilic compound.
In 1942, James Hamilton observed that prepubertal castration prevents the later development of male pattern baldness in mature men. In 1974, Julianne Imperato-McGinley of Cornell Medical College in New York attended a conference on birth defects. She reported on a group of intersex children in the Caribbean who appeared sexually ambiguous at birth, and were initially raised as girls, but then grew external male genitalia and other masculine characteristic after onset of puberty. These children, despite being raised as girls until puberty, were generally heterosexual, and were termed "Guevedoces" by their local community, which means "penis at twelve" in Spanish. Her research group found these children shared a genetic mutation, causing deficiency of the 5α-reductase enzyme and male hormone dihydrotestosterone (DHT), which was found to have been the etiology behind abnormalities in male sexual development. Upon maturation, these individuals were observed to have smaller prostates which were underdeveloped, and were also observed to lack incidence of male pattern baldness.
In 1975, copies of Imperato-McGinley's presentation were seen by P. Roy Vagelos, who was then serving as Merck's basic-research chief. He was intrigued by the notion that decreased levels of DHT led to the development of smaller prostates. Dr. Vagelos then sought to create a drug which could mimic the condition found in these children to treat older men who were suffering from benign prostatic hyperplasia.
Finasteride was developed by Merck under the code name MK-906. In 1992, finasteride (5 mg) was approved by the U.S. Food and Drug Administration (FDA) for treatment of BPH, which Merck marketed under the brand name Proscar. In 1997, Merck was successful in obtaining FDA approval for a second indication of finasteride (1 mg) for treatment of male pattern hair loss, which was marketed under the brand name Propecia.
Society and culture
Finasteride is the generic name of the drug and its INN, USAN, BAN, and JAN, while finastéride is its DCF. It is also known by its former developmental code names MK-906, YM-152, and L-652,931.
Finasteride is marketed primarily under the brand names Propecia, for pattern hair loss, and Proscar, for BPH, both of which are products of Merck & Co. There is 1 mg of finasteride in Propecia and 5 mg in Proscar. Merck's patent on finasteride for the treatment of BPH expired in June 2006. Merck was awarded a separate patent for the use of finasteride to treat pattern hair loss and it expired in November 2013. Finasteride is also marketed under a variety of other brand names throughout the world.
Men in the U.S. and Canada concerned about persistent sexual side effects "coined the phrase 'post-finasteride syndrome', which they say is characterized by sexual, neurological, hormonal and psychological side effects that can persist in men who have taken finasteride for hair loss or an enlarged prostate". In 2012, a health advocacy group called the Post-Finasteride Syndrome Foundation was formed with the primary goal of finding a cure for the reported syndrome and a secondary goal of raising awareness. A 2015 post in Health News Review noted that the foundation put out a press release timed to the publication of a review it had funded claiming that the NIH had recognized "post-finasteride syndrome"; in response to an inquiry, an NIH spokeswoman said the statement released by the foundation was inaccurate and not determined by the NIH. In 2016, Merck was a defendant in 1,370 product liability lawsuits which had been filed by customers alleging they have experienced persistent sexual side effects following cessation of treatment with finasteride.
From 2005 to 2009, the World Anti-Doping Agency banned finasteride because it was discovered that the drug could be used to mask steroid abuse. It was removed from the list effective January 1, 2009, after improvements in testing methods made the ban unnecessary. Athletes who used finasteride and were banned from international competition include skeleton racer Zach Lund, bobsledder Sebastien Gattuso, footballer Romário, and ice hockey goaltender José Théodore.
- Lemke TL, Williams DA (2008). Foye's Principles of Medicinal Chemistry (6th ed.). Lippincott Williams & Wilkins. pp. 1286–. ISBN 978-0-7817-6879-5.
- Buckingham J (1987). Dictionary of Organic Compounds. CRC Press. p. 3147. ISBN 978-0-412-54090-5.
- Morton I, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 121, 246. ISBN 978-94-011-4439-1.
- Blume-Peytavi U, Whiting DA, Trüeb RM (26 June 2008). Hair Growth and Disorders. Springer Science & Business Media. p. 369. ISBN 978-3-540-46911-7.
- Knezevich EL, Viereck LK, Drincic AT (January 2012). "Medical management of adult transsexual persons". Pharmacotherapy. 32 (1): 54–66. doi:10.1002/PHAR.1006. PMID 22392828.
- Proscar label
- Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ (October 2010). "Finasteride for benign prostatic hyperplasia". The Cochrane Database of Systematic Reviews (10): CD006015. doi:10.1002/14651858.CD006015.pub3. PMID 20927745.
- Varothai S, Bergfeld WF (July 2014). "Androgenetic alopecia: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 217–30. doi:10.1007/s40257-014-0077-5. PMID 24848508.
- Ferri, Fred F. (2014). Ferri's Clinical Advisor 2015 E-Book: 5 Books in 1. Elsevier Health Sciences. p. 580. ISBN 9780323084307.
- Azzouni F, Godoy A, Li Y, Mohler J (2012). "The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases". Adv Urol. 2012: 530121. doi:10.1155/2012/530121. PMC 3253436. PMID 22235201.
- Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M (February 2010). "An overview on 5alpha-reductase inhibitors". Steroids. 75 (2): 109–53. doi:10.1016/j.steroids.2009.10.005. PMID 19879888.
- Yamana K, Labrie F, Luu-The V (August 2010). "Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride". Hormone Molecular Biology and Clinical Investigation. 2 (3): 293–9. doi:10.1515/hmbci.2010.035. PMID 25961201.
- Bartsch G, Rittmaster RS, Klocker H (April 2000). "Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia". European Urology. 37 (4): 367–80. doi:10.1159/000020181. PMID 10765065.
- Burger A, Abraham DJ (20 February 2003). Burger's Medicinal Chemistry and Drug Discovery, Autocoids, Diagnostics, and Drugs from New Biology. Wiley. p. 439. ISBN 978-0-471-37030-7.
- Doherty AM (2003). Annual Reports in Medicinal Chemistry. Academic Press. pp. 353–. ISBN 978-0-12-040538-1.
- Sataloff RT, Sclafani AP (30 November 2015). Sataloff's Comprehensive Textbook of Otolaryngology: Head & Neck Surgery: Facial Plastic and Reconstructive Surgery. JP Medical Ltd. pp. 400–. ISBN 978-93-5152-459-5.
- "Treatment of Non-neurogenic Male LUTS | Uroweb".
- Wilt TJ, Macdonald R, Hagerty K, Schellhammer P, Tacklind J, Somerfield MR, Kramer BS (2010). "5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review". BJU Int. 106 (10): 1444–51. doi:10.1111/j.1464-410X.2010.09714.x. PMID 20977593.
- Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, Goodman PJ, Thompson IM (March 2018). "Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial". Journal of the National Cancer Institute. doi:10.1093/jnci/djy035. PMID 29534197.
- Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS (2016). "Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review". J Clin Aesthet Dermatol. 9 (7): 56–62. PMC 5023004. PMID 27672412.
- Kanti V1, Messenger A2, Dobos G1, Reygagne P3, Finner A4, Blumeyer A5, Trakatelli M6, Tosti A7,8, Del Marmol V9, Piraccini BM10, Nast A11, Blume-Peytavi U1. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):11-22. doi: 10.1111/jdv.14624. Epub 2017 Nov 27.
- "Propecia label" (PDF).
- Adil A, Godwin M (July 2017). "The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis". Journal of the American Academy of Dermatology. 77 (1): 136–141.e5. doi:10.1016/j.jaad.2017.02.054. PMID 28396101.
- Habif TP (23 April 2015). Clinical Dermatology. Elsevier Health Sciences. pp. 934–. ISBN 978-0-323-26607-9.
- Yim E, Nole KL, Tosti A (December 2014). "5α-Reductase inhibitors in androgenetic alopecia". Current Opinion in Endocrinology, Diabetes and Obesity. 21 (6): 493–8. doi:10.1097/MED.0000000000000112. PMID 25268732.
- Gupta AK, Charrette A (April 2014). "The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride". The Journal of Dermatological Treatment. 25 (2): 156–61. doi:10.3109/09546634.2013.813011. PMID 23768246.
- Levy LL, Emer JJ (August 2013). "Female pattern alopecia: current perspectives". International Journal of Women's Health. 5: 541–56. doi:10.2147/IJWH.S49337. PMC 3769411. PMID 24039457.
- Trüeb, Ralph M. (2017). "Discriminating in favour of or against men with increased risk of finasteride-related side effects?". Experimental Dermatology. 26: 527–528. doi:10.1111/exd.13155. ISSN 0906-6705. PMID 27489125.
[...] caution is recommended while prescribing oral finasteride to male-to-female transsexuals, as the drug has been associated with inducing depression, anxiety and suicidal ideation, symptoms that are particularly common in patients with gender dysphoria, who are already at a high risk.
- Wolverton SE (2007). Comprehensive Dermatologic Drug Therapy. Elsevier Health Sciences. ISBN 978-1-4377-2070-9.
- Burchum J, Rosenthal L. Lehne's Pharmacology for Nursing Care - E-Book. Elsevier Health Sciences. p. 802. ISBN 978-0-323-34026-7.
- Traish AM (2012). "5α-reductases in human physiology: an unfolding story". Endocr Pract. 18 (6): 965–75. doi:10.4158/EP12108.RA. PMID 23246684.
- Kirtschig, Gudula; Schaefer, Christof (2015). "Dermatological medications and local therapeutics": 467–492. doi:10.1016/B978-0-12-408078-2.00018-4.
In humans, [the use of finasteride] at the end of the first trimester could lead to hypospadia. Up to now, however, there are no available studies in humans. There is merely a case report on a malformation of the extremities on the right hand and left foot of a [female] child whose mother took finasteride because of hair loss (Sallout and Al Wadi 2009). However, this observation does not justify any causal connection.
- Sallout BI, Al Wadi KA (2009). "Aphalangia possibly linked to unintended use of finasteride during early pregnancy". Ann Saudi Med. 29 (2): 155–6. doi:10.4103/0256-4947.51805. PMC 2813641. PMID 19318745.
- FDA. "Summary of Key Safety Findings" (PDF). p. 98.
- FDA. Posted 9 June 2011. 5-alpha reductase inhibitors (5-ARIs): Label Change – Increased Risk of Prostate Cancer
- Walsh PC (April 2010). "Chemoprevention of prostate cancer". The New England Journal of Medicine. 362 (13): 1237–8. doi:10.1056/NEJMe1001045. PMID 20357287.
- Medicines and Healthcare products Regulatory Agency Drug Safety Update. December 2009 Finasteride: potential risk of male breast cancer
- Narula HS, Carlson HE (August 2014). "Gynaecomastia-pathophysiology, diagnosis and treatment". Nat Rev Endocrinol. 10 (11): 684–698. doi:10.1038/nrendo.2014.139. PMID 25112235.
- Deepinder F, Braunstein GD (2012). "Drug-induced gynecomastia: an evidence-based review". Expert opinion on drug safety. 11 (5): 779–795. doi:10.1517/14740338.2012.712109. PMID 22862307.
- Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF (April 2014). "Aldosterone antagonists for preventing the progression of chronic kidney disease". Cochrane Database of Systematic Reviews. 4: CD007004. doi:10.1002/14651858.CD007004.pub3. PMID 24782282.
- Aiman U, Haseeen MA, Rahman SZ (December 2009). "Gynecomastia: An ADR due to drug interaction". Indian Journal of Pharmacology. 41 (6): 286–7. doi:10.4103/0253-7613.59929. PMC 2846505. PMID 20407562.
- Trost L, Saitz TR, Hellstrom WJ (2013). "Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review". Sex Med Rev. 1 (1): 24–41. doi:10.1002/smrj.3. PMID 27784557.
- Belknap SM, Aslam I, Kiguradze T, Temps WH, Yarnold PR, Cashy J, Brannigan RE, Micali G, Nardone B, West DP (June 2015). "Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis". JAMA Dermatology. 151 (6): 600–6. doi:10.1001/jamadermatol.2015.36. PMID 25830296.
- FDA (11 April 2012). "Questions and Answers: Finasteride Label Changes". US FDA. Retrieved 26 October 2014.
- Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G (October 2010). "Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review". Archives of Dermatology. 146 (10): 1141–50. doi:10.1001/archdermatol.2010.256. PMID 20956649.
- Gur S, Kadowitz PJ, Hellstrom WJ (January 2013). "Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation". Expert Opinion on Drug Safety. 12 (1): 81–90. doi:10.1517/14740338.2013.742885. PMID 23173718.
- Frye SV (2006). "Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor". Curr Top Med Chem. 6 (5): 405–21. doi:10.2174/156802606776743101. PMID 16719800.
- Sudduth SL, Koronkowski MJ (1993). "Finasteride: the first 5α-reductase inhibitor". Pharmacotherapy. 13 (4): 309–25, discussion 325–9. doi:10.1002/j.1875-9114.1993.tb02739.x. PMID 7689728.
- Victor R. Preedy (2012). Handbook of Hair in Health and Disease. Springer Science & Business Media. pp. 89–. ISBN 978-90-8686-728-8.
- Jashin J. Wu (18 October 2012). Comprehensive Dermatologic Drug Therapy E-Book. Elsevier Health Sciences. pp. 361–. ISBN 1-4557-3801-8.
- Kim EH, Brockman JA, Andriole GL (January 2018). "The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia". Asian Journal of Urology. 5 (1): 28–32. doi:10.1016/j.ajur.2017.11.005. PMC 5780290. PMID 29379733.
- Rittmaster RS (January 1994). "Finasteride". N. Engl. J. Med. 330 (2): 120–5. doi:10.1056/NEJM199401133300208. PMID 7505051.
- Libecco JF, Bergfeld WF (April 2004). "Finasteride in the treatment of alopecia". Expert Opin Pharmacother. 5 (4): 933–40. doi:10.1517/14656518.104.22.1683. PMID 15102575.
- Shapiro J, Kaufman KD (June 2003). "Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss)". J. Investig. Dermatol. Symp. Proc. 8 (1): 20–3. doi:10.1046/j.1523-1747.2003.12167.x. PMID 12894990.
- Drury JE, Di Costanzo L, Penning TM, Christianson DW (July 2009). "Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex". The Journal of Biological Chemistry. 284 (30): 19786–90. doi:10.1074/jbc.C109.016931. PMC 2740403. PMID 19515843.
- Bostwick DG, Cheng L (24 January 2014). Urologic Surgical Pathology E-Book. Elsevier Health Sciences. pp. 402–. ISBN 978-0-323-08619-6.
- Robaire B, Henderson NA (May 2006). "Actions of 5alpha-reductase inhibitors on the epididymis". Molecular and Cellular Endocrinology. 250 (1–2): 190–5. doi:10.1016/j.mce.2005.12.044. PMID 16476520.
- Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, Wiren KM (2006). "A new look at the 5alpha-reductase inhibitor finasteride". CNS Drug Reviews. 12 (1): 53–76. doi:10.1111/j.1527-3458.2006.00053.x. PMID 16834758.
- Römer B, Gass P (December 2010). "Finasteride-induced depression: new insights into possible pathomechanisms". Journal of Cosmetic Dermatology. 9 (4): 331–2. doi:10.1111/j.1473-2165.2010.00533.x. PMID 21122055.
- Gunn BG, Brown AR, Lambert JJ, Belelli D (2011). "Neurosteroids and GABA(A) Receptor Interactions: A Focus on Stress". Frontiers in Neuroscience. 5: 131. doi:10.3389/fnins.2011.00131. PMC 3230140. PMID 22164129.
- Tian G, Stuart JD, Moss ML, Domanico PL, Bramson HN, Patel IR, Kadwell SH, Overton LK, Kost TA, Mook RA (1994). "17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1". Biochemistry. 33 (8): 2291–6. doi:10.1021/bi00174a041. PMID 8117686.
- Azeem A, Khan ZI, Aqil M, Ahmad FJ, Khar RK, Talegaonkar S (May 2009). "Microemulsions as a surrogate carrier for dermal drug delivery". Drug Development and Industrial Pharmacy. 35 (5): 525–47. doi:10.1080/03639040802448646. PMID 19016057.
- Hamilton, J (1942). "Male hormone stimulation is prerequisite and an incitant in common baldness". American Journal of Anatomy. 71 (3): 451–480. doi:10.1002/aja.1000710306.
- "The extraordinary case of the Guevedoces". BBC News. 2015-09-20. Retrieved 2018-09-03.
- Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (December 1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170): 1213–5. doi:10.1126/science.186.4170.1213. PMID 4432067.
- Isfort AH, Emerick JE, Paz RA (11 November 2016). "5-Alpha-Reductase Deficiency". WebMD. News & Perspective Drugs & Diseases CME & Education Academy Consult, Drugs & Diseases > Pediatrics: General Medicine.
- Freudenheim M (February 16, 1992). "Keeping the Pipeline Filled at Merck". The New York Times.
- Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. p. 443. ISBN 978-3-88763-075-1.
- I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 121–. ISBN 978-94-011-4439-1.
- Barrie W. Bycroft; David J. Payne (9 August 2013). Dictionary of Antibiotics and Related Substances: with CD-ROM, Second Edition. CRC Press. pp. 816–. ISBN 978-1-4822-8215-3.
- "Primary Patent Expirations for Selected High Revenue Drugs". RxNews. Prescription Solutions. Archived from the original on 21 March 2008.
- FDA. "Patent Expiration for Propecia". Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- Margo J (26 September 2012). "Looking at care with a critical eye". Australian Financial Review.
- "Post-Finasteride Syndrome Foundation official website".
- Hoffman, Richard (August 12, 2015). "Advocacy group spin may skew discussion on finasteride side effects". Health News Review.
- "Watch for these potential side effects in drug Trump reportedly takes for hair loss" Miami Herald. Retrieved 2018-10-17.
- Sandomir R (2006-01-19). "Skin Deep; Fighting Baldness, and Now an Olympic Ban". The New York Times. Retrieved 2010-05-02.
- Staff (28 October 2008). "WADA removes Finasteride from ban list". The Australian.
- Staff (9 October 2008). "WADA takes Romario's drug off banned list". Sydney Morning Herald.
- "Deferral of Blood and Plasma donors – Medications" (PDF). FDA. 28 July 1993. Retrieved 4 February 2017.
- Altman LK (1 February 2017). "Donald Trump's Longtime Doctor Says President Takes Hair-Growth Drug". The New York Times. Retrieved 25 February 2017.